Medicines Co. Downgraded After FDA Panel Rejects Drug

By | February 13, 2014

Scalper1 News

Drugmaker the Medicines Co. (MDCO) was suffering both on the stock market and in analyst opinion Thursday, a day after an FDA panel voted against approving its anti-platelet drug cangrelor. On Wednesday, trading on the firm’s shares were halted on the stock market after the panel voted 7-2 against approving the drug, which would be used to prevent clotting in patients undergoing cardiac stent procedures. The panel criticized the design of one of Scalper1 News

Scalper1 News